Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 11, pp 1901–1907 | Cite as

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

  • Evelina Martinenaite
  • Shamaila Munir Ahmad
  • Simone Kloch Bendtsen
  • Mia Aaboe Jørgensen
  • Stine Emilie Weis-Banke
  • Inge Marie Svane
  • Mads Hald AndersenEmail author
Focussed Research Review
  • 27 Downloads

Abstract

l-arginine depletion by regulatory cells and cancer cells expressing arginase-1 (Arg-1) is a vital contributor to the immunosuppressive tumor microenvironment in patients with cancer. We have recently described the existence of pro-inflammatory effector T cells that recognize Arg-1. Hence, Arg-1-specific self-reactive T cells are a naturally occurring part of the memory T-cell repertoire of the human immune system. Here, we further characterize a highly immunogenic epitope from Arg-1. We describe frequent T-cell-based immune responses against this epitope in patients with cancer, as well as in healthy donors. Furthermore, we show that Arg-1-specific T cells expand in response to the TH2 cytokine interleukin (IL)-4 without any specific stimulation. Arg-1-specific memory TH1 cells that respond to increased IL-4 concentration may, therefore, drive the immune response back into the TH1 pathway. Arg-1-specific T cells thus appear to have an important function in immune regulation. Because Arg-1 plays an important role in the immunosuppressive microenvironment in most cancers, an immune modulatory vaccination approach can readily be employed to tilt the balance away from immune suppression in these settings.

Keywords

Arginase Anti-regulatory T cells Immune-modulating vaccines IO112 PIVAC 18 

Abbreviations

Arg1

Arginase 1

BC

Breast cancer

HD

Healthy donor

MM

Malignant melanoma

TAM

Tumor-associated macrophages

TNTC

Too numerous to count

Notes

Author contributions

MHA designed and supervised the study. EM designed the experiments and analyzed the data. EM, SMA, SKB, MAJ, and SEWB performed experiments. IMS provided the relevant clinical material. All authors contributed to drafting the manuscript.

Funding

This work has been supported by grants from the Danish Cancer Society (Grant number R146-A9440-16-S2), Herlev Hospital (CCIT-Dk funding) and Innovation Fund Denmark (Grant number 8054-00058B).

Compliance with the ethical standards

Conflict of interest

Mads Hald Andersen has filed several patent applications based on the use of arginase for vaccinations. The rights of the patent applications have been transferred to Copenhagen University Hospital, Herlev, in accordance with the Danish Law of Public Inventions at Public Research Institutions. The capital region has licensed these patents to the company IO Biotech ApS, whose purpose is to develop immune-modulating vaccines for cancer treatments. Mads Hald Andersen is a shareholder and board member of IO Biotech ApS. Evelina Martinenaite is employed by IO Biotech ApS. Other authors declare no conflict of interest.

Ethical approval and ethical standards

The protocol was approved by the Scientific Ethics Committee for the Capital Region of Denmark (H-A-2009-013) and conducted in accordance with the provisions of the Declaration of Helsinki.

Informed consent

Written informed consent for the use of the PBMCs for research purposes was obtained from the patients and healthy donors prior to inclusion in the study.

References

  1. 1.
    Geiger R et al (2016) l-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167(3):829–842.  https://doi.org/10.1016/j.cell.2016.09.031 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zea AH et al (2004) L-Arginine modulates CD3ζ expression and T cell function in activated human T lymphocytes. Cell Immunol 232(1–2):21–31.  https://doi.org/10.1016/j.cellimm.2005.01.004 CrossRefGoogle Scholar
  3. 3.
    Rodriguez PC, Quiceno DG, Ochoa AC (2007) L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109(4):1568–1574.  https://doi.org/10.1182/blood-2006-06-031856 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    De Boniface J, Mao Y, Schmidt-mende J, Kiessling R, Poschke I (2012) Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology 1(8):1305–1312.  https://doi.org/10.4161/onci.21678 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lang S et al (2018) Clinical relevance and suppressive capacity of human MDSC subsets. Clin Cancer Res 24(19):4834–4844.  https://doi.org/10.1158/1078-0432.CCR-17-3726 CrossRefGoogle Scholar
  6. 6.
    Rodriguez PC et al (2009) Arginase I—producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553–1561.  https://doi.org/10.1158/0008-5472.CAN-08-1921 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rotondo R et al (2009) IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 125:887–893.  https://doi.org/10.1002/ijc.24448 CrossRefGoogle Scholar
  8. 8.
    Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022.  https://doi.org/10.1038/ni.2703 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Andersen MH (2016) Anti-regulatory T cells. Semin Immunopathol.  https://doi.org/10.1007/s00281-016-0593-x CrossRefGoogle Scholar
  10. 10.
    Andersen MH (2015) Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst 107(9):1–8.  https://doi.org/10.1093/jnci/djv154 CrossRefGoogle Scholar
  11. 11.
    Andersen MH (2018) The balance players of the adaptive immune system. Cancer Res 15:1379–1383.  https://doi.org/10.1158/0008-5472.CAN-17-3607 CrossRefGoogle Scholar
  12. 12.
    Martinenaite E et al (2018) Frequent adaptive immune responses against arginase-1. Oncoimmunology 7(3):1–9.  https://doi.org/10.1080/2162402X.2017.1404215 CrossRefGoogle Scholar
  13. 13.
    Jørgensen MA et al (2018) Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. Oncoimmunology.  https://doi.org/10.1080/2162402X.2018.1468957 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Martinenaite E, Ahmad SM, Svane IM, Andersen MH (2019) Peripheral memory T cells specific for Arginase-1. Cell Mol Immunol.  https://doi.org/10.1038/s41423-019-0231-3 CrossRefGoogle Scholar
  15. 15.
    Moodie Z, Price L, Janetzki S, Cedrik B (2012) Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 792:185–196.  https://doi.org/10.1007/978-1-62703-239-1_1 CrossRefGoogle Scholar
  16. 16.
    Cassetta L, Pollard JW (2018) Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 17(12):887–904.  https://doi.org/10.1038/nrd.2018.169 CrossRefGoogle Scholar
  17. 17.
    Munder M, Eichmann K, Morán JM, Centeno F, Soler G, Modolell M (1999) Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163(7):3771–3777Google Scholar
  18. 18.
    Yu W, Jiang N, Quake SR, Davis MM (2015) Clonal deletion prunes but does not eliminate self-specific alphabeta CD8(+) T lymphocytes. Immunity 42:929–941.  https://doi.org/10.1016/j.immuni.2015.05.001 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Namdar A et al (2018) Prophylactic DNA vaccine targeting Foxp3 + regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model. Cancer Immunol Immunother 67(3):367–379.  https://doi.org/10.1007/s00262-017-2088-6 CrossRefGoogle Scholar
  20. 20.
    Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E (2007) Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67(1):371–380.  https://doi.org/10.1158/0008-5472.CAN-06-2903 CrossRefGoogle Scholar
  21. 21.
    Munir S et al (2013) HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 73(6):1764–1776.  https://doi.org/10.1158/0008-5472.CAN-12-3507 CrossRefGoogle Scholar
  22. 22.
    Munir S, Andersen GH, Svane IM, Andersen MH (2013) The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology 2(4):e23991.  https://doi.org/10.4161/onci.23991 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Munir S, Andersen GH, Woetmann A, Ødum N, Becker JC, Andersen MH (2013) Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27(11):2251–2253.  https://doi.org/10.1038/leu.2013.118 CrossRefGoogle Scholar
  24. 24.
    Ahmad SM, Larsen SK, Svane IM, Andersen MH (2014) Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28(1):236–238.  https://doi.org/10.1038/leu.2013.261 CrossRefGoogle Scholar
  25. 25.
    Soerensen RB, Hadrup SR, Svane IM, Hjortso MC, Straten PT, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200–2210.  https://doi.org/10.1182/blood-2010-06-288498 CrossRefGoogle Scholar
  26. 26.
    Andersen MH (2012) CD4 responses against IDO. Oncoimmunology 1(7):1211–1212.  https://doi.org/10.4161/onci.20780 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Larsen SK et al (2013) Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia 27(12):2332–2340.  https://doi.org/10.1038/leu.2013.196 CrossRefGoogle Scholar
  28. 28.
    Martinenaite E et al (2016) CCL22-specific T Cells: modulating the immunosuppressive tumor microenvironment. Oncoimmunology 5(11):e1238541.  https://doi.org/10.1080/2162402X.2016.1238541 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.National Center for Cancer Immune Therapy (CCIT-dk)Copenhagen University Hospital HerlevHerlevDenmark
  2. 2.IO Biotech ApSCopenhagenDenmark
  3. 3.Department of Immunology and MicrobiologyUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations